Adverum Biotechnologies (Nasdaq:ADVM) - Aandelenkoers, Nieuws & Analyse

ADVM Overzicht aandelen

Adverum Biotechnologies, Inc., een bedrijf in een klinische fase, ontwikkelt productkandidaten voor gentherapie voor de behandeling van oogziekten.

Over het bedrijf

ADVM fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 50.03% per year

Risicoanalyse

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 14.7% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Adverum Biotechnologies, Inc. Concurrenten

Anixa Biosciences

NasdaqCM:ANIX

US$117.8m

Adicet Bio

NasdaqGM:ACET

US$103.0m

Precigen

NasdaqGS:PGEN

US$235.3m

Solid Biosciences

NasdaqGS:SLDB

US$221.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Adverum Biotechnologies
Historische aandelenkoersen
Huidige aandelenkoers	US$7.41
52 Week Hoogtepunt	US$29.70
52 Week Laag	US$6.38
Bèta	1.03
11 maand verandering	-1.59%
3 maanden verandering	10.60%
1 Jaar Verandering	-22.42%
33 jaar verandering	-67.36%
5 jaar verandering	-91.90%
Verandering sinds IPO	-97.05%

Recent nieuws en updates

Recent updates

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31

Rendement voor aandeelhouders

	ADVM	US Biotechs	US Markt
7D	-6.4%	-0.7%	-1.6%
1Y	-22.4%	19.8%	30.8%

Rendement versus industrie: ADVM underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: ADVM underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is ADVM's price volatile compared to industry and market?
ADVM volatility
ADVM Average Weekly Movement	7.8%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ADVM has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ADVM's weekly volatility has decreased from 13% to 8% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	121	Laurent Fischer	adverum.com

Adverum Biotechnologies, Inc., een bedrijf in een klinische fase, ontwikkelt gentherapieproductkandidaten voor de behandeling van oogziekten. De belangrijkste productkandidaat is ixoberogene soroparvovec (ADVM-022), een kandidaat voor gentherapie met enkelvoudige intravitreale injectie die gebruikt wordt voor de behandeling van patiënten met natte leeftijdsgebonden maculaire degeneratie en diabetisch macula-oedeem en die zich in fase 2 van de klinische studies bevindt. Het bedrijf ontwikkelt ADVM-062 (AAV.7m8-L-opsin), een nieuw product voor gentherapie voor de behandeling van blauwe kegel monochromie via een enkelvoudige IVT injectie.

Adverum Biotechnologies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Adverum Biotechnologies zich tot de beurswaarde?
ADVM fundamentele statistieken
Marktkapitalisatie	US$154.13m
Inkomsten(TTM)	-US$99.86m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.5x

Koers/Winstverhouding

Is ADVM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ADVM resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$68.53m
Brutowinst	-US$68.52m
Overige uitgaven	US$31.34m
Inkomsten	-US$99.86m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.80
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ADVM op de lange termijn?

Bekijk historische prestaties en vergelijking

ADVM Overzicht aandelen

Beloningen

Risicoanalyse

Adverum Biotechnologies, Inc. Concurrenten

NasdaqCM:ANIX

US$117.8m

NasdaqGM:ACET

US$103.0m

NasdaqGS:PGEN

US$235.3m

NasdaqGS:SLDB

US$221.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Price target decreased to US$3.67

Price target decreased to US$3.67

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

Price target increased to US$4.33

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Adverum Biotechnologies: An Uncertain Path Forward

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate